Safe handling of hazardous drugs

Online Journal of Issues in Nursing

Volumn 9, Issue 3, 2004, Pages

  Polovich, Martha ^a,b  

^a S Regional Health System Oncology   (United States)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Antineoplastic agents; Chemotherapy; Cytotoxic drugs; Hazardous drugs; Nurse safety; Occupational exposure; Safe handling precautions

Indexed keywords

CARCINOGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE;

ALLERGIC REACTION; AMES TEST; BIOSAFETY; CANCER CHEMOTHERAPY; CARCINOGENICITY; COST BENEFIT ANALYSIS; COUGHING; DANGEROUS GOODS; DIARRHEA; DIZZINESS; DRUG CONTAMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG TRANSPORT; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GENOTOXICITY; HEADACHE; HEALTH CARE; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HOSPITAL EQUIPMENT; HUMAN; INFORMATION DISSEMINATION; INGESTION; INJECTION; INSTRUMENTATION; LIVER INJURY; MEDICAL INFORMATION; NAUSEA; NURSE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; OCCUPATIONAL HEALTH; POLLUTION; PRACTICE GUIDELINE; PROTECTIVE CLOTHING; REVIEW; RISK ASSESSMENT; SAFETY; SKIN ABSORPTION; SKIN IRRITATION; SORE THROAT; STATISTICAL SIGNIFICANCE; URINALYSIS; URINARY EXCRETION; VOMITING; WASTE DISPOSAL; WORKPLACE;

EID: 5444264396     PISSN: 10913734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. American Society of Hospital Pharmacists. (1990). ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. American Journal of Hospital Pharmacy, 47, 1033-49.
2. Anderson, R.W., Puckett, W.H., Dana, W.J., Nguyen, T.V., Theiss, J.C., & Matney, T.S. (1982). Risk of handling injectable antineoplastic agents. American Journal of Hospital Pharmacy, 39, 1881-1887.
3. Bos, R.P., & Sessink, P.J.M. (1997). Biomonitoring of occupational exposure to cytotoxic anticancer drugs. Reviews on Environmental Health, 12(1), 43-58.
4. Brown, K.A., Esper, P., Kelleher, L.O., O'Neill, J.E.B., Polovich, M., & White, J.M. (Ed). (2001). Chemotherapy and biotherapy guidelines and recommendations for practice. Pittsburgh, PA: Oncology Nursing Society.
5. Cell Therapeutics. (2003). Trisenox package insert. Seattle, WA: Cell Therapeutics.
6. Code of Federal Regulations. (2003a). Occupational safety and health standards, Subpart A-general, Sec. 1910.2 [Title 29, Volume 5, p. 91.] Retrieved July 17, 2004 from http://frwebgate.access.gpo.gov/cgi-bin/get-cfr.cgi? TITLE=29&PART=1910&SECTION=2&TYPE=TEXT.
7. Code of Federal Regulations. (2003b). Occupational safety and health standards, Subpart Z--toxic and hazardous substances, Sec. 1910.1200 Hazard communication. [Title 29, Volume 6, p. 461-483.] Retrieved July 18, 2004 from http://frwebgate.access.gpo.gov/cgi-bin/get-cfr.cgi? TITLE=29&PART= 1910&SECTION=1200&TYPE=TEXT.
8. Code of Federal Regulations. (2003c). Occupational safety and health standards, Subpart Z--toxic and hazardous substances, Sec. 1910.1020 Access to employee exposure and medical records. [Title 29, Volume 6, p. 95-104.] Retrieved July 18, 2004 from http://frwebgate.access.gpo.gov/cgi-bin/get-cfr. cgi? TITLE=29&PART=1910&SECTION=1020&TYPE=TEXT.
9. Connor, T.H. (1993). An evaluation of the permeability of disposable polypropylene-based protective gowns to a battery of cancer chemotherapy drugs. Applied Occupational and Environmental Hygiene. 8, 785-789.
10. Connor, T.H., Anderson, R.W., Sessink, P.J.M., Broadfield, L., & Power, L.A. (1999). Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. American Journal of Health-System Pharmacy. 56, 1427-1432.
11. Connor, T.H., Anderson, R.W., Sessink, P.J., & Spivey, S.M. (2002). Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. American Journal of Health System Pharmacy, 59, 68-72.
12. Donner, A.L., (1978). Possible risk of working with antineoplastic drugs in horizontal laminar flow hoods. American Journal of Hospital Pharmacy, 35, 900.
13. Environmental Protection Agency. (2003). Introduction to hazardous waste identification. Solid waste and emergency response. Retrieved July 17, 2004 from www.epa.gov/epaoswer/hotline/training/hwid.pdf.
14. Falck, K., Grohn, P., Sorsa, M., Vainio, H., Heinonen, E., & Holsti, L.R. (1979). Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1(12),1250-1.
15. FDA. (2004). Approval statistics. Oncology tools. Food and drug administration. Retrieved April 14, 2004 from (www.accessdata.fda.gov/scripts/ cder/onctools/statistics.cfm.)
16. Harrison, B.R. (2001). Risks of handling cytotoxic drugs. In M.C. Perry (Ed.), The chemotherapy source book. (3rd Ed., pp. 566-582). Philadelphia, PA. Lippincott, Williams, & Wilkins.
17. Harrison, B.R., & Kloos, M.D. (1999). Penetration and splash protection of six disposable gown materials against fifteen antineoplastic drugs. Journal of Oncology Pharmacy Practice. 5, 61-66.
18. Hemminki, K., Kyyronen, P., & Lindbohm, M.L. (1985). Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytotoxic drugs, and other potential hazards in hospitals, based on registered information of outcome. Journal of Epidemiology and Community Health, 39, 141-147.
19. Kromhout, H., Hoek, F., Uitterhoeve, R., Huijbers, R., Overmars, R.F., Anzion, R., et al. (2000). Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Annals of Occupational Hygiene, 44(7), 551-560.
20. Labuhn, K., Valanis, B., Schoeny, R., Loveday, K., & Vollmer, W. M. (1998). Nurses' and pharmacists' exposure to antineoplastic drugs: findings from industrial hygiene scans and urine mutagenicity tests. Cancer Nursing, 21(2), 79-89.
21. Laidlaw, J.L, Connor, T.H., Theiss, J.C., Anderson, R.W., & Matney, T.S. (1985). Permeability of four disposable protective clothing materials to seven antineoplastic drugs. American Journal of Hospital Pharmacy, 42(11):2449-54.
22. Legal Information Institute. (2004) Workers compensation: an overview. Ithaca, New York: Cornell Law School. Retrieved September 24, 2004 from www.law.cornell.edu/topics/workers_compensation.html.
23. Mahon, S.M., Casperson, D.S., Yackzan, S., Goodner, S., Hasse, B., Hawkins, J., et al. (1994). Safe handling practices of cytotoxic drugs: The results of a chapter survey. Oncology Nursing Forum. 21, 1157-1165.
24. Martin, S., & Larsen, E. (2003). Chemotherapy-handling practices of outpatient and office-based oncology nurses. Oncology Nursing Forum, 30(4), 575-81.
25. McDevitt, J.J., Lees, P.S.J., & McDiarmid, M.A. (1993). Exposure of hospital pharmacists and nurses to antineoplastic agents. Journal of Occupational Medicine, 35, 57-60.
26. National Institute for Occupational Safety and Health. (2004). Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. Retrieved March 25, 2004 from www.cdc.gov/niosh/docs/2004- 165/pdfs/2004-165.pdf.
27. Ng, L.M., & Jaffe, N. (1970). Possible hazards of handling antineoplastic drugs. Pediatrics, 46(4), 648-9.
28. Nieweg, R.M., deBoer, M., Dubbleman, R.C., Gail, H.E., Hesselman, G.M., Lenssen, P.C., et al. (1994). Safe handling of antineoplastic drugs. Results of a survey. Cancer Nursing, 17(6), 501-511.
29. Occupational Safety and Health Administration. (1986). OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. American Journal of Hospital Pharmacy, 43, 1193-1204.
30. Occupational Safety and Health Administration. (1996). Controlling occupational exposure to hazardous drugs. American Journal of Health-System Pharmacy, 53, 1669-1685.
31. Occupational Safety and Health Administration. (1999). Technical manual, TED 1-0.15A, Section VI, Chapter 2, Retrieved May 4, 2004 from (www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html#2.)
32. PhaSeal. (2004). Product information. Retrieved May 4, 2004 from www.phaseal.com/siteUS/movies.asp?main=filmsmain&right=filmsright.
33. Polovich, M. (Ed.). (2003). Safe handling of hazardous drugs. Pittsburgh, PA: Oncology Nursing Press.
34. Power, L. A. (1983). Regulated handling of parenteral antineoplastic agents. Particulate and Microbial Control, 40, 1163-71.
35. Resource Conservation and Recovery Act (1976). Hazardous waste management. Title 42, Chapter 82, Subchapter III. Retrieved July 17, 2004 from www4.law.cornell.edu/uscode/42/ch82schIII.html
36. Rogers, B., & Emmett, E.A. (1987). Handling antineoplastic agents: urine mutagenicity in nurses. Image: Journal of Nursing Scholarship, 19(3), 108-113.
37. Selevan, S.G., Lindbohm, J.L., Hornung, J.W., & Hemminki, K. (1985). A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. New England Journal of Medicine, 313(19), 1173-8.
38. Sessink, P.J.M., Anzion, R.B.M., van der Broek, P.H.H., & Bos, R.P. (1992). Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharmacy Weekly Science, 14, 16-22.
39. Sessink, P.J.M., & Bos, R.P., (1999). Drugs hazardous to healthcare workers: evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Safety, 20(4), 347-359.
40. Sotaniemi, E.A., Sutinen, S., Arranto, A.J., Sutinen, S., & Sotaniemi, K.A. (1983). Liver damage in nurses handling cytotoxic agents. Acta Medica Scandinavica, 214(3), 181-9.
41. Stolar, M.H. (1988). ASHP national survey of hospital pharmaceutical services-1987. American Journal of Hospital Pharmacy, 45, 801-18.
42. Stolar, M.H., Power, L.A., & Viele, C.S. (1983). Recommendations for handling cytotoxic drugs in hospitals. American Journal of Hospital Pharmacy, 40, 63-71.
43. Stucker, I., Calliard, J.F., Collin, R., Gout, M., Poyen, D., & Hemon, D. (1990). Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scandinavian Journal of Environmental Health, 16 (2), 102-7.
44. U. S. Department of Commerce. (1999). Standard industry codes. Washington, DC: Author.
45. Vandenbroucke J. (2001). Quality assurance project in a university hospital-2 years of experience. European Journal of Pharmacy, 7(2), 60-68.
46. Vandenbroucke, J., & Robays, H. (2001). How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. Journal of Oncology Pharmacy Practice, 6(4),146-152.
47. Valanis, B.G., Vollmer, W.M., Labuhn, K., & Glass, A. (1997). Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. Journal of Occupational and Environmental Medicine, 39, 574-580.
48. Valanis, B.G., Vollmer, W.M. & Steele, P., (1999). Occupational exposure to antineoplastic agents: Selfreported miscarriages and stillbirths among nurses and pharmacists. Journal of Occupational and Environmental Medicine, 41, 632-638.
49. Wick, C., Slawson, M.H., Jorgenson, J.A., & Tyler, L.S. (2003). Using a closed-system protective device to reduce personnel to antineoplastic agents. American Journal of Health-System Pharmacy, 60, 2314-20.